Skip to main content

Advertisement

Figure 7 | BMC Public Health

Figure 7

From: An evaluation of emerging vaccines for childhood meningococcal disease

Figure 7

Seroresponse rate in Menactra and Menomune for MenA, MenC, MenY and MenW-135 ((1) Keyserling, H., et al: Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med, 2005, 159: 907-13; (2) Bilukha, O.O. and N. Rosenstein: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2005, 54: 1-21; (3) Jackson, L. A., et al: Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49: e1-10; (4) Reisinger, K. S., et al : Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009, 16: 1810-1815.)

Back to article page